These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31913160)

  • 1. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG
    Appl Immunohistochem Mol Morphol; 2021 Jan; 29(1):49-55. PubMed ID: 31913160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M; Khambata-Ford S; Copie-Bergman C; Huang L; Juco J; Hofman V; Hofman P
    PLoS One; 2017; 12(8):e0183023. PubMed ID: 28797130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
    Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verification and validation of the anti-PD-L1 antibody, Clone 22C
    Brennan S; O'Neill J; Kennedy S
    J Clin Pathol; 2023 Oct; 76(10):678-683. PubMed ID: 35820775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparability of laboratory-developed and commercial PD-L1 assays in non-small cell lung carcinoma.
    Naso JR; Wang G; Banyi N; Derakhshan F; Shokoohi A; Ho C; Zhou C; Ionescu DN
    Ann Diagn Pathol; 2021 Feb; 50():151590. PubMed ID: 33157383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 testing of non-small cell lung cancer using different antibodies and platforms: a Swiss cross-validation study.
    Savic S; Berezowska S; Eppenberger-Castori S; Cathomas G; Diebold J; Fleischmann A; Jochum W; Komminoth P; McKee T; Letovanec I; Jasarevic Z; Rössle M; Singer G; von Gunten M; Zettl A; Zweifel R; Soltermann A; Bubendorf L
    Virchows Arch; 2019 Jul; 475(1):67-76. PubMed ID: 31127385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Fujimoto D; Yamashita D; Fukuoka J; Kitamura Y; Hosoya K; Kawachi H; Sato Y; Nagata K; Nakagawa A; Tachikawa R; Date N; Sakanoue I; Hamakawa H; Takahashi Y; Tomii K
    Anticancer Res; 2018 Dec; 38(12):6891-6895. PubMed ID: 30504406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect Clinical Validation of a Programmed Death-Ligand 1 Laboratory-Developed Test for Gastric/Gastroesophageal Junction Adenocarcinoma with 22C3 Antibody Concentrate.
    Kim JM; Kim B; Kim E; Jang M; Cho JH; Lee HS; Kwak Y; Huang L; Krishnan R; Bai SY; Mounawar M; Kim KM
    Mol Diagn Ther; 2022 Nov; 26(6):679-688. PubMed ID: 36125657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
    Zajac M; Scott M; Ratcliffe M; Scorer P; Barker C; Al-Masri H; Rebelatto MC; Walker J
    Diagn Pathol; 2019 Sep; 14(1):99. PubMed ID: 31477145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formalin fixation for optimal concordance of programmed death-ligand 1 immunostaining between cytologic and histologic specimens from patients with non-small cell lung cancer.
    Koomen BM; van der Starre-Gaal J; Vonk JM; von der Thüsen JH; van der Meij JJC; Monkhorst K; Willems SM; Timens W; 't Hart NA
    Cancer Cytopathol; 2021 Apr; 129(4):304-317. PubMed ID: 33108706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms.
    Koppel C; Schwellenbach H; Zielinski D; Eckstein S; Martin-Ortega M; D'Arrigo C; Schildhaus HU; Rüschoff J; Jasani B
    Mod Pathol; 2018 Nov; 31(11):1630-1644. PubMed ID: 29946185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
    Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
    Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C; Albitar M; Zerba K; Sudarsanam S; Chizhevsky V; Jin C; Burns V
    J Clin Pathol; 2018 Dec; 71(12):1078-1083. PubMed ID: 30275099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of PD-L1 clone 22C3 immunohistochemical stain on two Ventana DISCOVERY autostainer models: detailed protocols, test performance characteristics, and interobserver reliability analyses.
    Basu A; Chiriboga L; Narula N; Zhou F; Moreira AL
    J Histotechnol; 2020 Dec; 43(4):174-181. PubMed ID: 33245263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer.
    Rimm DL; Han G; Taube JM; Yi ES; Bridge JA; Flieder DB; Homer R; West WW; Wu H; Roden AC; Fujimoto J; Yu H; Anders R; Kowalewski A; Rivard C; Rehman J; Batenchuk C; Burns V; Hirsch FR; Wistuba II
    JAMA Oncol; 2017 Aug; 3(8):1051-1058. PubMed ID: 28278348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interobserver agreement in programmed cell death-ligand 1 immunohistochemistry scoring in nonsmall cell lung carcinoma cytologic specimens.
    Sinclair W; Kobalka P; Ren R; Beshai B; Lott Limbach AA; Wei L; Mei P; Li Z
    Diagn Cytopathol; 2021 Feb; 49(2):219-225. PubMed ID: 33104298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.
    Adam J; Le Stang N; Rouquette I; Cazes A; Badoual C; Pinot-Roussel H; Tixier L; Danel C; Damiola F; Damotte D; Penault-Llorca F; Lantuéjoul S
    Ann Oncol; 2018 Apr; 29(4):953-958. PubMed ID: 29351573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.